Rogiers, A. http://orcid.org/0000-0003-3716-2559
Leys, C.
De Cremer, J.
Awada, G.
Schembri, A.
Theuns, P.
De Ridder, M.
Neyns, B.
Article History
Received: 28 June 2019
Accepted: 31 October 2019
First Online: 19 November 2019
Compliance with ethical standards
:
: The study (ExternalRef removed Identifier: NCT02673970) on “Biomarkers for the activity of immune checkpoint inhibitor therapy in patients with advanced melanoma”, was approved by the Ethical Committee (EC) of the Universitair Ziekenhuis Brussel in 2014, and the sub-study in April 2016.
: AR has consulting and advisory role in the Bristol-Myers Squibb and Merck Sharp & Dome. GA received travel accommodations from the Merck Sharp & Dome and Pfizer, research grant from the Pfizer and Novartis. AS is a full-time employee of the Cogstate Ltd., the company that provided the computerized cognitive tests in this study. MD received research agreement from the Brainlab AG, and has consulting or advisory role in the Novalis Certification Expert. BN received honoraria from the Bristol-Myers Squibb, Merck Sharp & Dome, Novartis, and Roche, has consulting or advisory role in the Bristol-Myers Squibb, Merck Sharp & Dome, Novartis, Roche, Speakers’ Bureau-Novartis, and received travel, accommodations, and expenses from the Amgen, Bristol-Myers Squibb, Merck Sharp & Dome, Novartis, and Roche.The other authors have no conflict of interest to declare.